BOSTON, August 2, 2006 — Predix Pharmaceuticals announced that it has entered into an exclusive collaboration and licensing agreement with Amgen for the development of novel, orally available S1P1 modulators for the treatment of multiple autoimmune diseases. The two companies will produce existing Predix preclinical compounds and new S1P1 modulators. As part of the transaction, Predix will receive an upfront payment of $20 million, with the potential to earn up to an additional $287.5 million in milestone payments.
Goodwin Procter partner Christopher Denn represented Predix in this matter.